Business Wire

CA-ENLIGHTED

23.5.2023 14:31:34 CEST | Business Wire | Press release

Share
Enlighted to Deliver Heavyweight Energy Savings, Productivity and Sustainability at New WWE HQ

Today Enlighted, a leading proptech company owned by Siemens, announced a new engagement with World Wrestling Entertainment (WWE) to support its vision of a smart, energy efficient headquarters. The leader in global entertainment that can be seen in more than 1 billion homes worldwide will use Enlighted’s intelligent lighting control, smart sensors, IoT data services and real time location services (RTLS) to achieve occupancy-based energy savings, optimal space management and provide the most productive environment for WWE employees.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005437/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

WWE is headquartered in Stamford, Connecticut, with over 400,000 square feet of multi-purpose space including office space, studios, production and post-production facilities, conferencing, event, and outdoor terrace spaces. With the size and complexity of space types, it is essential for WWE to understand and optimize its real estate footprint using technology and software with the flexibility to address a range of uses. As part of a major renovation and digital transformation initiative, with almost 2,000 sensors over a wireless, fault-tolerant network at WWE will enable:

Enlighted Lighting Solution: Occupancy-based intelligent lighting control with flexible configurations for task tuning, daylight harvesting and efficient lighting of WWE spaces will result in bottom line energy savings and progression of WWE’s carbon neutrality.

Enlighted Data Services: Collecting data 65 times per second from sensors that measure movement, temperature and power, WWE will use specialized visualization dashboards to derive key insights for space design decisions.

Location Intelligence: WWE will use the same lighting sensing environment to reliably track assets, ranging from high value assets (memorabilia, collectibles) to operational assets (mail carts, merchandise samples, packages) in real-time for movement analysis and improved inventory management.

With Enlighted’s lighting controls as the foundation, WWE will be solving multiple IoT use cases and utilizing the open APIs, WWE will have central management, a ‘single pane of glass’ into operations.

“The new WWE headquarters is comprised of spaces intended for a variety of very different uses,” said Rajan Mehta, Chief Technology Officer, WWE. “The Enlighted IoT Smart Building technology will make it possible for us to realize enormous energy savings, increase our operating efficiencies and use data to capture building activity for intelligent data-driven space decisions. IoT-based asset tracking and process flow improvements will make our headquarters truly a smart building.”

“Space utilization isn’t just a matter of knowing how many people are in an office or production facility at a given moment—it’s about understanding how employees and guests are moving and interacting with spaces,” said Stefan Schwab, CEO of Enlighted. “The lighting-based sensors at WWE will capture vast amounts of data that WWE can use for a refined view of activity across all of their buildings. With the scalability of cloud storage, the company will be able to identify trends and preferences as they examine building usage data over time.”

About Enlighted

Enlighted is a leading proptech provider of IoT solutions at the intersection of people, space, and work. We offer a unique combination of cognitive environmental IoT sensors and lighting controls that connect to intelligent workplace experience apps, offering a singular, scalable, interoperable solution to address a spectrum of building, space, and productivity needs. Our customers leverage these solutions to enable occupant well-being, greater business efficiencies and momentum toward their sustainability goals. Enlighted is part of Building Robotics, Inc., a Siemens company. For more information, please visit us at enlightedinc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005437/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye